Table 1 Data abstracted from studies with active follow‐up of chlamydial and gonococcal reinfection among men.
| Author, year (reference) | Population | n | Follow‐up method | Follow‐up period | % of enrolled men with follow‐up (n) | % of men with repeat chlamydia (n) | % of men with repeat gonorrhea (n) | % of men with repeat gonorrhoea/chlamydia (n) | % of female data (n) |
|---|---|---|---|---|---|---|---|---|---|
| Peterman et al, 200645 | STD, clinic‐based; Newark, Denver and Long Beach: chlamydia and/or gonorrhoea‐infected subset of 2419 clinics, patients aged 15–39 years, enrolled in HIV prevention counselling study | 246 M, 133 F | Scheduled 3 month follow‐up visit at respective STD clinic | 3 months* | 83.3 (205/246) | 9.8 (112) | 14.9 (68) | 20.0† (25) | CHLAMYDIA: 10.7 (84) GONORRHOEA: 3.6 (30) |
| Bernstein et al, 200646 | STD, clinic‐based; Baltimore, Maryland: people diagnosed as having gonorrhoea at public STD clinic | 548 M, 119 F | Scheduled follow‐up visit or follow‐up by disease investigation specialists | 3 months | 24.3 (133/548) | NA | 30.8 (41/133) | NA | GONORRHOEA: 28.9 (13/45) |
| Ellen et al, 200647 | Various venues; Baltimore and Denver: asymptomatic chlamydia and/or gonorrhoea infected males aged 13–25 years | 314 M | Scheduled follow‐up visits at 1 and 4 months | 4 months | 44.3‡ (139/314) | NA | NA | 6.5§ (9/139) | NA |
| Golden et al, 200543 | Population based; King County, Washington: partner‐notified heterosexuals who returned mailed rescreening kits | 57 M, 124 F | Mailed retesting kit 3 months after treatment | 3 months | 35.8¶ (221/618) | 10.7 (6/56) | 0.0 (0/14) | NA | CHLAMYDIA: 7.6 (11/144) GONORRHOEA: 16.7 (2/12) |
| Golden et al, 200529 | Population based; King County, Washington: gonorrhoea and/or chlamydia‐infected women and heterosexual men with untreated partners | 646 M, 2105 F | Reinterview and retest | 19 weeks | 61.3 (396/646) | 10.1 (27/267) | 7.0 (11/157) | 9.1‡ (37/396) | CHLAMYDIA: 12.3 GONORROHEA: 7.0 CHLAMYDIA/GONORROHEA: 12.0 |
| Sparks et al, 200448 | STD, clinic based; King County, Washington: asymptomatic chlamydia and/or gonorrhoea infected heterosexual males and females aged ⩾14 years | 84 M, 38 F | Mailed or clinic retesting 10–24 weeks after treatment | 24 weeks | 63.4 (71/112) | 16.0 (6/38) | 0.0 (0/9) | NA | CHLAMYDIA: 0 (0/20) GONORRHOEA: 25 (1/4) |
| Dunne et al, 200444 | Various venues; Baltimore, Denver and San Francisco: chlamydia‐infected men | 361 M | Scheduled follow‐up visits at 1 and 4 months | 4 months | 76.0 (272/358) | 11.4 (31/272) | NA | NA | NA |
| Kjaer et al, 200049 | Population based; Ringkjobing, Denmark: chlamydia‐infected general practice patients aged ⩾18 years who had not been treated with antibiotics in previous 4 weeks | 12 M, 30 F | Serial mailed specimens collected at 2, 4, 8, 12 and 24 weeks | 24 weeks | 83.3** (10/12) | 11.1†† (1/9) | NA | NA | 12.0‡‡ (3/25) |
F, female; M, male; NA, not applicable; STD, sexually transmitted disease.
*Follow‐up period was for 1 year, but abstracted data are limited to first follow‐up at 3 months.
†Repeat chlamydia/gonorrohea defined as either chlamydial or gonococcal infection in men coinfected with chlamydia and gonorrhoea at baseline.
‡Follow‐up is defined as participants with at least one follow‐up visit. If 1‐month visit was not available, 4‐month visit was used.
§Repeat chlamydia/gonorrohea defined as chlamydial infection at follow‐up in men with chlamydia at baseline or gonococcal infection at follow‐up in men with gonorrhoea at baseline.
¶Measure is overall follow‐up rate. Male‐specific data were not available.
**Defined as at least one mailed specimen collected 2–24 weeks after baseline mailed specimen.
††Reported reinfection data are defined as a new infection between 2 and 12 weeks after initial infection.
‡‡Repeat chlamydia/gonorrohea defined as chlamydia infection at follow‐up in men with chlamydia at baseline or gonococcal infection at follow‐up in men with gonorrhoea at baseline or either infection in men coinfected with chlamydia and gonorrhoea at baseline.